Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business
Ipsen Pharma Strong 2021 financial performance with total-sales growth of 12.3% at CER1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating margin of 29.6%)…